Vasoreactivity in Carriers of Genetic Polymorphisms

Heidelberg University

Status and phase

Unknown

Phase 1

Conditions

Healthy

Treatments

Drug: sodium nitroprusside, bradykinin, acetylcholine

Study type

Interventional

Funder types

Other

Identifiers

NCT00160888

K004

Details and patient eligibility

About

The objective of the study is to assess the impact of genetic variation (especially polymorphisms of the gene coding endothelial nitric oxide synthase (eNOS) and the bradykinin B2 receptor gene) on venous and arterial responsiveness to vasodilators in healthy individuals without cardiovascular risk factors.

Full description

Study I: Using the dorsal hand vein compliance technique dose-response curves to bradykinin and sodium nitroprusside will be obtained in healthy volunteers during preconstriction with phenylephrine and after pretreatment with a single dose of 500 mg i.v. acetylsalicylic acid.

Study II: Using venous occlusion plethysmography dose-response curves to acetylcholine, sodium nitroprusside and L-NG-monomethyl-arginine (L-NMMA) will be obtained in healthy volunteers pretreated with a single dose of 500mg i.v. acetylsalicylic acid.

Sex

All

Ages

18 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

age: 18 - 70
gender: male
good state of health

Exclusion criteria

known condition causing endothelial dysfunction (e.g. diabetes, hyperlipidaemia, arterial hypertension, smoking, homocysteinemia)
regular medication and/or treatment with drugs within the last 4-6 weeks (exclusion has to be decided in each case)
acute or chronic illness
methylxanthines and alcohol during 12 hours before the study
nicotine during 1 year before the study
drug and/or alcohol abuse
pregnancy or lactation